Showing 2644 results
- Story /
- Media Release /Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1] …
- Media Release /Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS…
- Media Release /Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1…
- Media Release /Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
- Key Release /In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary…
- Media Release /PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will…
- Media Release /Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic…
- Media Release /Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and…
- Media Release /Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or…
Pagination
- ‹ Previous page
- 1
- …
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- …
- 265
- › Next page